Correlation between IL-17 and inflammatory bowel disease.

Q3 Medicine
Hiba T Majeed, Zahraa Y Motaweq
{"title":"Correlation between IL-17 and inflammatory bowel disease.","authors":"Hiba T Majeed, Zahraa Y Motaweq","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) is a protracted, persistent gastrointestinal disease that is distinguished by recurring, persistent inflammation of the digestive tract. IBD, including Crohn's disease and ulcerative colitis, is characterized by persistent inflammation due to immune dysregulation. Interleukin -17 (IL-17) contributes significantly to the pathophysiology of IBD, as highlighted in the context of the provided research. There is a strong correlation between IL-17 inhibitors and the onset or exacerbation of IBD, with IL-17 inhibitor treatment being linked to gastrointestinal inflammatory events such as IBD and colitis. The goal of the current study was to determine the relationship between IBD disease activity and serum IL-17 levels in individuals with IBD. This case-control study included 102 IBD patients and 48 normal individuals as a control group. Blood samples were used for measuring IL-17 levels using the enzyme-linked immunosorbent assay. Levels of IL-17 were increased in patients compared with the control group (p=0.0001). IL-17 levels were significantly elevated in patients aged 1-15 years, 31-45 years and 16-30 years. IL-17 levels showed significant differences between two types of inflammatory bowel disease being elevated in Crohn's disease more than ulcerative colitis (p=0.001). IL-17 demonstrated significant differences in IL-17 levels between male and female in patients and controls groups (p=0.0001). In conclusion, patients with IBD have higher serum levels of IL-17, indicating that these cytokines may have a role in the development and pathophysiology of Crohn's disease and ulcerative colitis. Overall, monitoring IL-17 levels could serve as valuable biomarkers for assessing IBD severity and guiding treatment decisions.</p>","PeriodicalId":39724,"journal":{"name":"The Egyptian journal of immunology / Egyptian Association of Immunologists","volume":"32 1","pages":"56-62"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Egyptian journal of immunology / Egyptian Association of Immunologists","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Inflammatory bowel disease (IBD) is a protracted, persistent gastrointestinal disease that is distinguished by recurring, persistent inflammation of the digestive tract. IBD, including Crohn's disease and ulcerative colitis, is characterized by persistent inflammation due to immune dysregulation. Interleukin -17 (IL-17) contributes significantly to the pathophysiology of IBD, as highlighted in the context of the provided research. There is a strong correlation between IL-17 inhibitors and the onset or exacerbation of IBD, with IL-17 inhibitor treatment being linked to gastrointestinal inflammatory events such as IBD and colitis. The goal of the current study was to determine the relationship between IBD disease activity and serum IL-17 levels in individuals with IBD. This case-control study included 102 IBD patients and 48 normal individuals as a control group. Blood samples were used for measuring IL-17 levels using the enzyme-linked immunosorbent assay. Levels of IL-17 were increased in patients compared with the control group (p=0.0001). IL-17 levels were significantly elevated in patients aged 1-15 years, 31-45 years and 16-30 years. IL-17 levels showed significant differences between two types of inflammatory bowel disease being elevated in Crohn's disease more than ulcerative colitis (p=0.001). IL-17 demonstrated significant differences in IL-17 levels between male and female in patients and controls groups (p=0.0001). In conclusion, patients with IBD have higher serum levels of IL-17, indicating that these cytokines may have a role in the development and pathophysiology of Crohn's disease and ulcerative colitis. Overall, monitoring IL-17 levels could serve as valuable biomarkers for assessing IBD severity and guiding treatment decisions.

IL-17与炎症性肠病的相关性
炎症性肠病(IBD)是一种长期、持续性的胃肠道疾病,以消化道反复、持续性炎症为特征。包括克罗恩病和溃疡性结肠炎在内的IBD,其特征是由于免疫失调引起的持续炎症。白细胞介素-17 (IL-17)在IBD的病理生理中起着重要作用,这一点在所提供的研究中得到了强调。IL-17抑制剂与IBD的发病或恶化之间存在很强的相关性,IL-17抑制剂治疗与胃肠道炎症事件(如IBD和结肠炎)有关。本研究的目的是确定IBD疾病活动性与IBD患者血清IL-17水平之间的关系。本病例对照研究包括102例IBD患者和48例正常人作为对照组。血液样本采用酶联免疫吸附法测定IL-17水平。与对照组相比,患者IL-17水平升高(p=0.0001)。IL-17水平在1-15岁、31-45岁和16-30岁患者中显著升高。两种炎症性肠病患者IL-17水平差异显著,克罗恩病患者IL-17水平高于溃疡性结肠炎患者(p=0.001)。IL-17在患者和对照组中,男性和女性IL-17水平有显著差异(p=0.0001)。综上所述,IBD患者血清IL-17水平较高,提示这些细胞因子可能在克罗恩病和溃疡性结肠炎的发生发展和病理生理中发挥作用。总的来说,监测IL-17水平可以作为评估IBD严重程度和指导治疗决策的有价值的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
52
期刊介绍: Information not localized
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信